红色生物技术的全球市场：市场规模和占有率分析（依应用、产品和最终用户）、工业需求预测（截至 2030 年）

主要亮点

预计2023年全球红色生技市场规模将达5,767亿美元，2030年将达1,1723亿美元，复合年增长率超过10.5%。

对临床试验、药物发现、带因者筛检和诊断的需求不断增长，以及遗传疾病盛行率的上升，正在推动产业扩张。

关键见解

2023年生物製药产量将以25.0%的占有率引领产业，预计未来10年将继续引领产业。

2023年，人用疫苗将以30.0%的占有率引领产业，预计未来10年将持续。

到 2023 年，北美地区将以约 55% 的占有率引领产业，预计未来几年将呈现更稳定的成长。

亚太地区正以最快的速度取得进展。 这是由于该地区来自国内外生物技术公司的资金不断增加，以及大量的传染病和慢性病患者。

本报告分析了全球红色生物技术市场，包括市场的基本结构和最新情况、主要促进和抑制因素以及全球、依地区和主要国家的市场规模前景（以货币计算） ，2017-2030），依应用程式、产品和最终用户划分的详细趋势、当前市场竞争状况以及主要公司概况。

目录

第一章研究范围

第二章研究方法

第 3 章执行摘要

第 4 章市场指标

第五章产业展望

• 市场动态
  • 趋势
  • 促进因素
  • 抑制因素/课题
  • 促进/抑制因子影响分析
• 新型冠状病毒感染 (COVID-19) 的影响
• 波特五力分析

第六章世界市场

• 摘要
• 市场收入：依应用分类（2017-2030 年）
• 市场收入：依产品分类（2017-2030 年）
• 市场收入：以最终用户划分（2017-2030 年）
• 市场收入：依地区划分（2017-2030 年）

第七章北美市场

• 摘要
• 市场收入：依应用分类（2017-2030 年）
• 市场收入：依产品分类（2017-2030 年）
• 市场收入：以最终用户划分（2017-2030 年）
• 市场收入：依国家/地区划分（2017-2030 年）

第八章欧洲市场

第9章亚太市场

第10章拉丁美洲市场

第十一章中东及非洲市场

第12章美国市场

• 摘要
• 市场收入：依应用分类（2017-2030 年）
• 市场收入：依产品分类（2017-2030 年）
• 市场收入：以最终用户划分（2017-2030 年）

第十三章加拿大市场

第14章德国市场

第十五章法国市场

第十六章英国市场

第十七章义大利市场

第十八章西班牙市场

第十九章日本市场

第20章中国市场

第21章印度市场

第22章澳洲市场

第23章韩国市场

第24章巴西市场

第25章墨西哥市场

第26章沙乌地阿拉伯市场

第27章南非市场

第 28 章阿联酋 (UAE) 市场

第29章竞争态势

• 市场参与者及其提供的产品/服务的列表
• 主要公司的竞争基准
• 各大公司的产品基准
• 近期策略发展状况

第30章公司简介

• Pfizer Inc.
• F. Hoffmann-La Roche Ltd.
• Merck KGaA
• AstraZeneca PLC
• Takeda Pharmaceutical Company Limited
• Amgen Inc.
• Regeneron Pharmaceuticals Inc.
• Gilead Sciences Inc.
• Novartis AG

第31章附录

Key Highlights

The red biotechnology market generated a value of USD 576.7 billion in 2023, and it will increase to USD 1,172.3 billion, advancing at more than 10.5% compound annual growth rate, by 2030.

The increasing need for it in clinical trials, drug discovery, carrier screening, and diagnostics, along with the rising incidence of genetic disorders aid the industry expansion.

Effective product development as well as genetic engineering relating to new drugs for treating life-threatening ailments are the key benefits of red biotechnology.

The increasing technological advancement rate in gene sequencing platforms, rising investment from private bodies and government for large-scale biotechnology plans, and substantial acceptance of red biotechnology across different applications like veterinary sciences, tissue engineering, and poultry farming, resulted in the industry expansion.

The increasing incidence of cancer and the surging use of this technology in cancer research & diagnostics are major drivers for this industry.

These technologies are employed for producing combination vaccines, including those that target Hepatitis A, Hepatitis B, polio, and diphtheria at once.

The rising count of R&D initiatives by major players, particularly in the area of stem cells, is a major trend in this industry.

Likewise, the pandemic of COVID-19 and a rising count of research studies discovering the use of this method for developing medicines, vaccines, and diagnostic tools assist industry expansion.

Key Insights

Biopharmaceutical production led the industry in 2023, with a 25.0% share, and it will further remain leading throughout this decade.

The increasing need for proteins, antibodies, antisense oligonucleotides, RNA, and DNA for diagnostic and therapeutic purposes is boosting the biopharmaceutical production category growth.

Gene therapy is likely to propel at the fastest compound annual growth rate in the years to come. The increasing incidence of genetic disorders as well as cancers is driving this category.

The human vaccines category led the industry in 2023, with a share of 30.0%, and it will continue this trend throughout this decade.

The human vaccines category growth is because of the increasing occurrence of infectious disease outbreaks and the rising prevalence of chronic ailments.

The biopharmaceutical industry was the largest contributor to the industry in 2023, with a 40.0% share, and it is likely to remain the largest during this decade.

The enhancing biopharmaceutical production infrastructure and R&D globally, to discover new molecule entities & vaccines against infectious ailments is driving the human vaccines category growth.

North America led the industry in 2023, with approximately 55% share, and it will further advance at a robust rate in the years to come.

The dominance of North America is because of the increasing incidence of rare, genetic, and chronic illnesses; the high technological improvement rate in the healthcare sector, and the rising number of R&D initiatives.

APAC is advancing at the fastest rate. This is because of the rising funding from both overseas and domestic biotech firms in this region and an enormous pool of patients with infectious and chronic ailments.

The red biotechnology industry is fragmented in nature, with the significant existence of large-scale companies.

These companies are involved in product launches, new product development, agreements, mergers, partnerships, and product approval to enhance their market presence.

Table of Contents

Chapter 1. Research Scope

• 1.1. Research Objectives
• 1.2. Market Definition
• 1.3. Analysis Period
• 1.4. Market Size Breakdown by Segments
  • 1.4.1. Market size breakdown, by application
  • 1.4.2. Market size breakdown, by product
  • 1.4.3. Market size breakdown, by end user
  • 1.4.4. Market size breakdown, by region
  • 1.4.5. Market size breakdown, by country
• 1.5. Market Data Reporting Unit
  • 1.5.1. Value
• 1.6. Key Stakeholders

Chapter 2. Research Methodology

• 2.1. Secondary Research
  • 2.1.1. Paid
  • 2.1.2. Unpaid
  • 2.1.3. P&S Intelligence database
• 2.2. Primary Research
• 2.3. Market Size Estimation
• 2.4. Data Triangulation
• 2.5. Currency Conversion Rates
• 2.6. Assumptions for the Study
• 2.7. Notes and Caveats

Chapter 3. Executive Summary

Chapter 4. Market Indicators

Chapter 5. Industry Outlook

• 5.1. Market Dynamics
  • 5.1.1. Trends
  • 5.1.2. Drivers
  • 5.1.3. Restraints/challenges
  • 5.1.4. Impact analysis of drivers/restraints
• 5.2. Impact of COVID-19
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Bargaining power of buyers
  • 5.3.2. Bargaining power of suppliers
  • 5.3.3. Threat of new entrants
  • 5.3.4. Intensity of rivalry
  • 5.3.5. Threat of substitutes

Chapter 6. Global Market

• 6.1. Overview
• 6.2. Market Revenue, by Application (2017-2030)
• 6.3. Market Revenue, by Product (2017-2030)
• 6.4. Market Revenue, by End User (2017-2030)
• 6.5. Market Revenue, by Region (2017-2030)

Chapter 7. North America Market

• 7.1. Overview
• 7.2. Market Revenue, by Application (2017-2030)
• 7.3. Market Revenue, by Product (2017-2030)
• 7.4. Market Revenue, by End User (2017-2030)
• 7.5. Market Revenue, by Country (2017-2030)

Chapter 8. Europe Market

• 8.1. Overview
• 8.2. Market Revenue, by Application (2017-2030)
• 8.3. Market Revenue, by Product (2017-2030)
• 8.4. Market Revenue, by End User (2017-2030)
• 8.5. Market Revenue, by Country (2017-2030)

Chapter 9. APAC Market

• 9.1. Overview
• 9.2. Market Revenue, by Application (2017-2030)
• 9.3. Market Revenue, by Product (2017-2030)
• 9.4. Market Revenue, by End User (2017-2030)
• 9.5. Market Revenue, by Country (2017-2030)

Chapter 10. LATAM Market

• 10.1. Overview
• 10.2. Market Revenue, by Application (2017-2030)
• 10.3. Market Revenue, by Product (2017-2030)
• 10.4. Market Revenue, by End User (2017-2030)
• 10.5. Market Revenue, by Country (2017-2030)

Chapter 11. MEA Market

• 11.1. Overview
• 11.2. Market Revenue, by Application (2017-2030)
• 11.3. Market Revenue, by Product (2017-2030)
• 11.4. Market Revenue, by End User (2017-2030)
• 11.5. Market Revenue, by Country (2017-2030)

Chapter 12. U.S. Market

• 12.1. Overview
• 12.2. Market Revenue, by Application (2017-2030)
• 12.3. Market Revenue, by Product (2017-2030)
• 12.4. Market Revenue, by End User (2017-2030)

Chapter 13. Canada Market

• 13.1. Overview
• 13.2. Market Revenue, by Application (2017-2030)
• 13.3. Market Revenue, by Product (2017-2030)
• 13.4. Market Revenue, by End User (2017-2030)

Chapter 14. Germany Market

• 14.1. Overview
• 14.2. Market Revenue, by Application (2017-2030)
• 14.3. Market Revenue, by Product (2017-2030)
• 14.4. Market Revenue, by End User (2017-2030)

Chapter 15. France Market

• 15.1. Overview
• 15.2. Market Revenue, by Application (2017-2030)
• 15.3. Market Revenue, by Product (2017-2030)
• 15.4. Market Revenue, by End User (2017-2030)

Chapter 16. U.K. Market

• 16.1. Overview
• 16.2. Market Revenue, by Application (2017-2030)
• 16.3. Market Revenue, by Product (2017-2030)
• 16.4. Market Revenue, by End User (2017-2030)

Chapter 17. Italy Market

• 17.1. Overview
• 17.2. Market Revenue, by Application (2017-2030)
• 17.3. Market Revenue, by Product (2017-2030)
• 17.4. Market Revenue, by End User (2017-2030)

Chapter 18. Spain Market

• 18.1. Overview
• 18.2. Market Revenue, by Application (2017-2030)
• 18.3. Market Revenue, by Product (2017-2030)
• 18.4. Market Revenue, by End User (2017-2030)

Chapter 19. Japan Market

• 19.1. Overview
• 19.2. Market Revenue, by Application (2017-2030)
• 19.3. Market Revenue, by Product (2017-2030)
• 19.4. Market Revenue, by End User (2017-2030)

Chapter 20. China Market

• 20.1. Overview
• 20.2. Market Revenue, by Application (2017-2030)
• 20.3. Market Revenue, by Product (2017-2030)
• 20.4. Market Revenue, by End User (2017-2030)

Chapter 21. India Market

• 21.1. Overview
• 21.2. Market Revenue, by Application (2017-2030)
• 21.3. Market Revenue, by Product (2017-2030)
• 21.4. Market Revenue, by End User (2017-2030)

Chapter 22. Australia Market

• 22.1. Overview
• 22.2. Market Revenue, by Application (2017-2030)
• 22.3. Market Revenue, by Product (2017-2030)
• 22.4. Market Revenue, by End User (2017-2030)

Chapter 23. South Korea Market

• 23.1. Overview
• 23.2. Market Revenue, by Application (2017-2030)
• 23.3. Market Revenue, by Product (2017-2030)
• 23.4. Market Revenue, by End User (2017-2030)

Chapter 24. Brazil Market

• 24.1. Overview
• 24.2. Market Revenue, by Application (2017-2030)
• 24.3. Market Revenue, by Product (2017-2030)
• 24.4. Market Revenue, by End User (2017-2030)

Chapter 25. Mexico Market

• 25.1. Overview
• 25.2. Market Revenue, by Application (2017-2030)
• 25.3. Market Revenue, by Product (2017-2030)
• 25.4. Market Revenue, by End User (2017-2030)

Chapter 26. Saudi Arabia Market

• 26.1. Overview
• 26.2. Market Revenue, by Application (2017-2030)
• 26.3. Market Revenue, by Product (2017-2030)
• 26.4. Market Revenue, by End User (2017-2030)

Chapter 27. South Africa Market

• 27.1. Overview
• 27.2. Market Revenue, by Application (2017-2030)
• 27.3. Market Revenue, by Product (2017-2030)
• 27.4. Market Revenue, by End User (2017-2030)

Chapter 28. U.A.E. Market

• 28.1. Overview
• 28.2. Market Revenue, by Application (2017-2030)
• 28.3. Market Revenue, by Product (2017-2030)
• 28.4. Market Revenue, by End User (2017-2030)

Chapter 29. Competitive Landscape

• 29.1. List of Market Players and their Offerings
• 29.2. Competitive Benchmarking of Key Players
• 29.3. Product Benchmarking of Key Players
• 29.4. Recent Strategic Developments

Chapter 30. Company Profiles

• 30.1. Pfizer Inc.
  • 30.1.1. Business overview
  • 30.1.2. Product and service offerings
  • 30.1.3. Key financial summary
• 30.2. F. Hoffmann-La Roche Ltd.
  • 30.2.1. Business overview
  • 30.2.2. Product and service offerings
  • 30.2.3. Key financial summary
• 30.3. Merck KGaA
  • 30.3.1. Business overview
  • 30.3.2. Product and service offerings
  • 30.3.3. Key financial summary
• 30.4. AstraZeneca PLC
  • 30.4.1. Business overview
  • 30.4.2. Product and service offerings
  • 30.4.3. Key financial summary
• 30.5. Takeda Pharmaceutical Company Limited
  • 30.5.1. Business overview
  • 30.5.2. Product and service offerings
  • 30.5.3. Key financial summary
• 30.6. Amgen Inc.
  • 30.6.1. Business overview
  • 30.6.2. Product and service offerings
  • 30.6.3. Key financial summary
• 30.7. Regeneron Pharmaceuticals Inc.
  • 30.7.1. Business overview
  • 30.7.2. Product and service offerings
  • 30.7.3. Key financial summary
• 30.8. Gilead Sciences Inc.
  • 30.8.1. Business overview
  • 30.8.2. Product and service offerings
  • 30.8.3. Key financial summary
• 30.9. Novartis AG
  • 30.9.1. Business overview
  • 30.9.2. Product and service offerings
  • 30.9.3. Key financial summary

Chapter 31. Appendix

• 31.1. Abbreviations
• 31.2. Sources and References
• 31.3. Related Reports